Creative Biolabs expands Fc engineering tools for therapeutic antibodies

Creative Biolabs has expanded its Fc engineering suite to help drug developers tune antibody immune activity for cancer, autoimmune disease, and other therapeutic uses. The platform is designed to boost cell-killing functions when needed or silence immune signaling to reduce safety risks.

Why it matters: - Fc engineering can change how therapeutic antibodies interact with the immune system. - The new platform is aimed at helping developers increase anti-tumor activity, reduce off-target toxicity, and preserve dosing properties such as half-life. - The expansion reflects growing demand for customized immunotherapies that need more precise immune control.

What happened: - Creative Biolabs announced an expanded Fc engineering suite on June 24, 2026, in Shirley, New York. - The platform adds targeted modifications to the fragment crystallizable, or Fc, region of antibodies. - The company says the system is built to support both immune activation and immune evasion, depending on the therapeutic goal.

The details: - The portfolio focuses on three main Fc-modulation goals: ADCC enhancement, CDC optimization and Fc effector silencing. - For oncology programs, Creative Biolabs uses glycoengineering, including afucosylation, and amino acid mutagenesis to improve binding between antibody Fc regions and FcγRIIIa/CD16a on natural killer cells. - The company says those afucosylated, ADCC-optimized platforms can increase antibody-dependent cellular cytotoxicity. - The platform also targets complement-dependent cytotoxicity by improving engagement between IgG and the C1q complement protein. - Creative Biolabs says that approach helps trigger membrane attack complex formation and tumor cell lysis. - For autoimmune disorders, viral infections, neutralizing antibodies and targeted payload delivery systems, the company uses mutations such as LALA/LALA-PG and N297A-mediated aglycosylation to block binding to FcγRs and C1q. - Those changes are intended to stop immune activation while preserving target binding. - The company says removing core fucose from N-linked glycans reduces steric hindrance and strengthens FcγRIIIa binding. - Creative Biolabs also says the engineered antibodies maintain binding to the neonatal Fc receptor, or FcRn, which helps preserve pharmacokinetics and serum half-life.

Between the lines: - The update is positioned around a common antibody-development tradeoff: stronger immune killing versus lower safety risk. - The platform suggests Creative Biolabs is trying to give developers more control over both ends of that spectrum without sacrificing antibody durability in the body. - A lead scientist at Creative Biolabs said the technologies are meant to help researchers move beyond wild-type IgG limitations and tune immune responses more predictably.

What's next: - Creative Biolabs says researchers can use the customized Fc engineering solutions as part of broader antibody discovery and optimization services. - The company is pitching the tools to pharmaceutical teams looking to improve the in vivo performance of therapeutic candidates. - No specific launch timeline, customer program or clinical partnership was disclosed.